MIM
RVNC

Monashee Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Monashee Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-85,000
Closed -$2.29M – 69
2022
Q3 		$2.29M Buy
+85,000
New +$1.72M 0.85% 19
2020
Q1 		– Sell
-85,000
Closed -$1.38M – 95
2019
Q4 		$1.38M Buy
+85,000
New +$1.32M 1.29% 31
2017
Q4 		– Hold
0
– – – 29

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Monashee Investment Management's RVNC Position: Q4 2022 in Review

Monashee Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 85,000 shares — an estimated $2.29M sold.

Monashee Investment Management first reported a position in RVNC in Q4 2019 and held it in 2 quarters. The position peaked at $2.29M in Q3 2022. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

  • Monashee Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Monashee Investment Management sold 85,000 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $2.29M.
  • Monashee Investment Management first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 2 quarters.
  • Monashee Investment Management's Revance Therapeutics, Inc. position peaked at $2.29M in Q3 2022.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on Monashee Investment Management's 13F filing for Q4 2022, filed 9 Feb 2023.